Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding AG    ROG   CH0012032048


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Roche : rises on word of COVID trial win, new test and European cancer drug nod

share with twitter share with LinkedIn share with facebook
09/18/2020 | 01:19pm EDT
FILE PHOTO: Workers clean windows of a building of Roche in Rotkreuz

Roche shares closed higher on Friday after the Swiss drugmaker said a study had shown its drug Actemra helped against COVID-19 and announced the release of a new antibody test as well as a European recommendation for a liver cancer cocktail.

Hospital patients taking Actemra, also called RoActemra, were 44% less likely to need ventilators or die than patients who got a placebo plus normal care, the company said, citing data from its Empacta phase III trial done in several countries including the United States.

The news is a boost for Roche after Actemra, a retooled rheumatoid arthritis medicine that fights inflammation, failed a separate late-stage clinical trial earlier this year in patients hospitalised with severe COVID-19 related pneumonia.

"The EMPACTA trial demonstrated that Actemra/RoActemra can reduce the need for mechanical ventilation in patients with COVID-19 associated pneumonia," said Levi Garraway, Roche's chief medical officer and head of global product development.

The shares rose 1.8% on Friday, making Roche the best performing company on Switzerland's benchmark index.

Empacta is the first global phase III COVID-19 clinical trial using minority patients, Roche said, adding this group, including Hispanic, Black and Native American patients, is often underrepresented in studies and has been hit harder by the pandemic than other groups.

Roche, which already has an COVID-19 antibody test that detects a patient's immune response to the virus's outer shell, said its new test targets antibodies that develop in response to the virus's spike.

The test is released in markets accepting the CE mark, and Roche is also seeking U.S. emergency approval.

The Basel-based company also said a European Medicines Agency panel recommended its Tecentric-Avastin cocktail be approved against hepatocellular carcinoma. The European Commission generally follows the panel's recommendation within months.

(Reporting by John Revill and John Miller; Editing by Thomas Seythal, Christopher Cushing and Philippa Fletcher)

share with twitter share with LinkedIn share with facebook
All news about ROCHE HOLDING AG
10/30GLOBAL MARKETS LIVE : Alphabet, Amazon, Starbucks…
10/30CHUGAI PHARMACEUTICAL : Results from the Investigator-Initiated Phase I Study of..
10/30ROCHE : SAP, Roche and Tenthpin Partner to Create New Standard for Clinical Tria..
10/29REGENERON PHARMACEUTICALS : COVID-19 Outpatient Trial Prospectively Demonstrates..
10/29CHUGAI PHARMACEUTICAL : Contribution of Para-transit Vehicles to Welfare Service..
10/29ROCHE HOLDINGS AG : UBS keeps its Buy rating
10/29ROCHE : Tecentriq in combination with Avastin approved in China for people with ..
10/29REGENERON'S REGN-COV2 ANTIBODY COCKT : Prospective data from ongoing Phase 2/3 C..
10/29ROCHE : Tecentriq in combination with Avastin approved in China for people with ..
10/29ROCHE : Tecentriq in combination with Avastin approved in China for people with ..
More news
Sales 2020 60 216 M 65 654 M 65 654 M
Net income 2020 14 527 M 15 839 M 15 839 M
Net cash 2020 3 238 M 3 530 M 3 530 M
P/E ratio 2020 17,7x
Yield 2020 3,16%
Capitalization 252 B 275 B 275 B
EV / Sales 2020 4,13x
EV / Sales 2021 3,80x
Nbr of Employees 97 735
Free-Float 83,6%
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 379,06 CHF
Last Close Price 294,75 CHF
Spread / Highest target 47,9%
Spread / Average Target 28,6%
Spread / Lowest Target -3,31%
EPS Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
Paul Bulcke Non-Executive Director
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG-6.13%275 049
JOHNSON & JOHNSON-6.01%361 159
PFIZER INC.-9.44%196 047
MERCK & CO., INC.-17.31%191 944
NOVARTIS AG-22.21%177 493
ABBVIE INC.-3.89%150 187